Compare SRRK & CACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | CACC |
|---|---|---|
| Founded | 2012 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | 2018 | 1996 |
| Metric | SRRK | CACC |
|---|---|---|
| Price | $56.23 | $599.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 2 |
| Target Price | $56.17 | ★ $505.00 |
| AVG Volume (30 Days) | ★ 981.1K | 103.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.00 |
| EPS | N/A | ★ 25.04 |
| Revenue | N/A | ★ $2,317,200,000.00 |
| Revenue This Year | N/A | $91.73 |
| Revenue Next Year | $534.24 | $3.58 |
| P/E Ratio | ★ N/A | $23.40 |
| Revenue Growth | N/A | ★ 7.16 |
| 52 Week Low | $27.07 | $401.90 |
| 52 Week High | $58.49 | $668.86 |
| Indicator | SRRK | CACC |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 56.55 |
| Support Level | $45.81 | $535.20 |
| Resistance Level | $58.49 | $621.52 |
| Average True Range (ATR) | 2.38 | 18.47 |
| MACD | 0.63 | 2.43 |
| Stochastic Oscillator | 93.21 | 64.31 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.